Our Pricing

Buy Wegovy Online UK: Cheapest Prices From £69.00

Published on: June 03, 2026

Looking to buy Wegovy online UK cheapest prices? At Cured Pharmacy, you'll find genuine UK-licensed Wegovy (semaglutide) injection pens from £79.00, with transparent upfront pricing, free clinical consultation by UK prescribers, and 100% discreet packaging delivered to your door. Our superintendent pharmacist Tarun Kumar and the clinical team have supported thousands of UK patients in their weight management journeys with prescription-only GLP-1 treatments.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics a natural hormone that regulates appetite and food intake by acting on areas of the brain involved in hunger control.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average weight reduction of 14.9% of their initial body weight over 68 weeks, compared to 2.4% in the placebo group [1]. The medication works by slowing gastric emptying, reducing appetite, and increasing feelings of fullness after meals, helping patients adhere to reduced-calorie diets more comfortably.

Wegovy is administered as a once-weekly subcutaneous injection, with dosing gradually increased over 16-20 weeks to minimise gastrointestinal side effects. The treatment must be combined with a reduced-calorie diet and increased physical activity for optimal results, and all patients require ongoing clinical supervision by a UK-registered prescriber [2].

Wegovy Dosing Schedule and What to Expect

Most patients begin noticing appetite reduction within the first few weeks of treatment, with measurable weight loss typically becoming evident by week 8-12 [1]. Clinical trials showed that the majority of weight loss occurred during the first 60 weeks of treatment, with weight stabilisation thereafter when combined with lifestyle modifications.

Your UK prescriber will monitor your progress through regular clinical reviews, typically every 12 weeks initially. If you haven't achieved at least 5% weight loss after 12 weeks on the maintenance dose, your prescriber will reassess whether Wegovy remains the appropriate treatment option for you, in line with NICE guidance [3].

Gradual Dose Escalation Protocol

Wegovy follows a carefully structured dose escalation schedule approved by the MHRA to improve tolerability. You'll start with 0.25 mg once weekly for four weeks, then increase to 0.5 mg, 1 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg [2]. Each dose increase occurs at four-week intervals, allowing your body to adapt gradually.

If you experience persistent gastrointestinal side effects such as nausea or vomiting, your prescriber may recommend delaying the next dose increase by an additional four weeks. This individualised approach helps maximise treatment adherence whilst minimising discomfort during the titration phase.

Common Side Effects and How to Manage Them

The most frequently reported side effects with Wegovy are gastrointestinal, including nausea (44% of patients in clinical trials), diarrhoea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%) [2]. These effects are usually mild to moderate, most common during dose escalation, and tend to decrease over time as your body adjusts to the medication.

To minimise nausea, eat smaller, more frequent meals rather than large portions, avoid high-fat or heavily spiced foods, and stay well-hydrated throughout the day. Injecting Wegovy at bedtime rather than morning may help some patients sleep through initial nausea. If side effects become severe or persistent, contact your prescriber—they may recommend temporarily reducing your dose or pausing escalation.

Rare but serious side effects include pancreatitis (inflammation of the pancreas), gallbladder problems, and hypoglycaemia if used alongside other diabetes medications. Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Wegovy carries a boxed warning in the US regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [2].

Who Can Use Wegovy and Who Should Avoid It

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment [2]. If you're planning pregnancy, discuss discontinuing Wegovy with your prescriber at least two months before conception.

Caution is required in patients with a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, or renal impairment. Your prescriber will review your complete medical history and current medications during consultation to identify any potential contraindications or drug interactions that could affect your suitability for Wegovy treatment.

Eligibility Criteria for Wegovy Treatment

Wegovy is licensed in the UK for adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [3]. Your prescriber will calculate your BMI and assess your medical history during the online consultation to determine eligibility.

NICE recommends considering GLP-1 receptor agonists like Wegovy as part of a specialist weight management service, particularly for patients who have not achieved adequate weight loss with diet, exercise, and behavioural interventions alone [3]. At Cured Pharmacy, our UK-registered clinical team conducts thorough assessments to ensure Wegovy is clinically appropriate and safe for each individual patient.

Buy Wegovy Online UK: How Cured Pharmacy Works

Purchasing Wegovy through Cured Pharmacy is straightforward and fully compliant with UK regulations. Start by completing our free online clinical assessment, which takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications. Our UK-registered prescribers review every assessment individually—there are no automatic approvals.

If Wegovy is deemed clinically appropriate for you, your prescription is issued electronically and sent directly to our GPhC-registered pharmacy (registration number 9012511). We dispense only genuine UK-licensed Wegovy pens sourced through authorised channels, never grey-market imports. Your medication is packaged discreetly with no external branding and dispatched via tracked courier for next-day delivery across the UK.

Our transparent pricing means you'll see the exact cost before completing your consultation—no hidden fees or surprise charges at checkout. If your prescriber determines Wegovy isn't suitable, you won't be charged, and they may suggest alternative treatments or recommend consulting your NHS GP for further evaluation. Ongoing prescriptions require periodic clinical reviews to monitor your progress and ensure continued safety and efficacy.

Wegovy vs Other Weight Loss Treatments Available in the UK

Non-injectable options such as orlistat (a lipase inhibitor) and naltrexone/bupropion combinations remain available for patients who prefer oral medications or have contraindications to GLP-1 treatments. However, clinical trial data consistently shows greater average weight loss with GLP-1 receptor agonists compared to older oral agents [4]. Your prescriber will discuss all suitable options during your consultation, considering your individual circumstances, preferences, and clinical needs.

All prescription weight loss medications work best when combined with sustainable lifestyle changes including a balanced reduced-calorie diet and regular physical activity. Medications are tools to support—not replace—behavioural modifications. Your prescriber may recommend additional resources such as dietitian referrals or structured weight management programmes to optimise your long-term success.

Comparing GLP-1 Receptor Agonists

Several GLP-1-based treatments are now licensed in the UK for weight management, each with distinct characteristics. Wegovy (semaglutide) is administered once weekly and demonstrated 14.9% average weight loss in the STEP trials [1]. Saxenda (liraglutide) requires daily injections and showed approximately 8% weight loss in the SCALE trials [4]. Newer dual-agonist treatments targeting both GLP-1 and GIP receptors have shown even greater efficacy in clinical studies, with some trials reporting average weight reductions exceeding 20% [5].

Your choice between these options depends on multiple factors including your BMI, comorbidities, injection frequency preference, side effect profile, and cost considerations. Once-weekly injections like Wegovy offer greater convenience and may improve long-term adherence compared to daily alternatives, though individual responses vary significantly.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and must be used under medical supervision as part of a comprehensive weight management programme including diet and exercise.